Year :
2024
| Month :
April
| Volume :
18
| Issue :
4
| Page :
ZC05 - ZC08
Full Version
Vitronectin Levels in Leukocyte-platelet Rich Fibrin, Injectable-platelet Rich Fibrin, and Serum: A Cross-sectional Study
Published: April 1, 2024 | DOI: https://doi.org/10.7860/JCDR/2024/69728.19251
Anirudh B Acharya, Aditi Lokhande, Swetha Acharya, Mihir Kulkarni, Srinath Thakur
1. Assistant Professor, Department of Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates.
2. Consultant; Private Practitioner (Periodontics), Bengaluru, Karnataka, India.
3. Research Scholar, Department of Oral Pathology, JSS Dental College, Mysuru, Karnataka, India.
4. Associate Professor, Department of Periodontics, SDM College of Dental Sciences and Hospital, Dharwad, Karnataka, India.
5. Former Professor, Department of Periodontics, SDM College of Dental Sciences and Hospital, Dharwad, Karnataka, India.
Correspondence Address :
Dr. Anirudh B Acharya,
Assistant Professor, Department of Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates.
E-mail: abacharya@gmail.com
Abstract
Introduction: Platelet-rich Fibrin (PRF) is an autologous platelet concentrate preparation containing several proteins that aid in healing. Vitronectin is one of these proteins that has not been quantified in all types of PRF. Various protocols have been suggested to alter the yield of different components of PRF to enhance wound healing. Hence, it is beneficial to know the vitronectin levels in PRF.
Aim: To detect, estimate, and compare the levels of vitronectin in two PRF protocols and serum.
Materials and Methods: The present cross-sectional study conducted in the Department of Periodontics at the SDM College of Dental Sciences and Hospital. Dharwad, Karnataka, India from January 2019 to June 2020 involved 12 systemically and periodontally healthy volunteers. Blood was obtained from each volunteer to collect and prepare serum, Leukocyte-PRF (L-PRF), and injectable-PRF (i-PRF), respectively. Three distinct samples-supernatant, exudate, and clot-were collected and categorised into seven groups (L-PRF supernatant, L-PRF exudate, L-PRF clot, i-PRF supernatant, i-PRF exudate, i-PRF clot, blood serum) that were assayed for levels of vitronectin. The data were statistically analysed using the independent t-test, one-way Analysis of Variance (ANOVA), and Newman-Keuls Post-hoc procedures.
Results: The mean age was 24.92±2.57 years. Vitronectin was detected and estimated in all the samples. Vitronectin levels ranged from 64.09±0.04 ng/mL to 64.20±0.21 ng/mL. One-way ANOVA applied to test between and within groups was significant (p=0.049). A statistically significant difference was observed only between L-PRF exudate and serum (p=0.05).
Conclusion: The comparable levels of vitronectin in L-PRF and i-PRF observed in present study suggest that vitronectin in these two PRF protocols may aid wound healing.
Keywords
Blood platelets, Blood protein, Enzyme-linked immunosorbent assay, Glycoprotein, Wound healing
DOI: 10.7860/JCDR/2024/69728.19251
Date of Submission: Jan 20, 2024
Date of Peer Review: Feb 13, 2024
Date of Acceptance: Feb 26, 2024
Date of Publishing: Apr 01, 2024
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Jan 22, 2024
• Manual Googling: Feb 10, 2024
• iThenticate Software: Feb 24, 2024 (5%)
ETYMOLOGY: Author Origin
EMENDATIONS: 6
|